Pembrolizumab + Gemcitabine + Cisplatin + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Carcinoma
Conditions
Biliary Tract Carcinoma
Trial Timeline
Jul 10, 2020 → Mar 25, 2025
NCT ID
NCT04924062About Pembrolizumab + Gemcitabine + Cisplatin + Placebo
Pembrolizumab + Gemcitabine + Cisplatin + Placebo is a phase 3 stage product being developed by Merck for Biliary Tract Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04924062. Target conditions include Biliary Tract Carcinoma.
What happened to similar drugs?
2 of 20 similar drugs in Biliary Tract Carcinoma were approved
Approved (2) Terminated (0) Active (18)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04924062 | Phase 3 | Completed |
| NCT04003636 | Phase 3 | Completed |
| NCT03924856 | Phase 3 | Active |
Competing Products
20 competing products in Biliary Tract Carcinoma